GlassScriptPhysician profile
Edgar Jay B Evangelista
NPI 1669693081
$19,329.73
in general payments reported to CMS, 2019-2025
68 companies · $2,869 in 2025
The $2,869 reported for 2025 was more than what 79% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,445 · 2020: $1,942 · 2021: $3,417 · 2022: $2,965 · 2023: $3,008 · 2024: $2,683 · 2025: $2,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,130 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $319 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,130.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $318.75 |
| Education | $111.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,158.76 | 2021-2025 | |
| Emd Serono, INC. | $1,929.32 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $1,258.26 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,074.56 | 2019-2025 | |
| Biogen, INC. | $1,016.65 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Amgen INC. | $788.93 | 2019-2024 | Uplizna, Aimovig |
| Celgene Corporation | $654.52 | 2021-2025 | Zeposia |
| Sk Life Science, INC. | $567.92 | 2020-2024 | |
| Eisai INC. | $551.62 | 2020-2025 | |
| Lundbeck LLC | $523.21 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $496.65 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $479.42 | 2020-2025 | Acthar |
| Argenx US, INC. | $464.74 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Avanir Pharmaceuticals, INC. | $438.36 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $422.97 | 2020-2025 | Austedo Xr |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Jay Evangelista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.